Press Releases

  • Cyxone makes further strides with Rabeximod phase IIb trial by signing CRO EGeen Inc.

    July 19, 2019 08:15 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has signed an agreement with EGeen Inc., a clinical research organization (CRO), for conducting its upcoming clinical phase IIb trial with Rabeximod in rheumatoid arthritis (RA) in select Eastern European countries. Cyxone is now, together with several partners, finalizing the necessary applications for permission to run its phase IIb multicenter study in both Western and Eastern Europe. The first application has been submitted and the remaining, up to eight, applications are expected to be submitted within the next six months.  

  • Cyxone announce dosing of first volunteer in T20K’s first-in-human trial

    July 12, 2019 10:09 (CEST)
    Regulatory

    Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment of multiple sclerosis (MS). The clinical phase I study is estimated to be concluded during the second half of 2019.

  • Cyxone submits first application to start clinical phase IIb trial with Rabeximod

    July 5, 2019 09:24 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of rheumatoid arthritis (RA). This first application will be followed by an application to the Competent Authority in Poland during the third quarter of 2019, and subsequently, by applications to the relevant regulatory authorities in additional European countries. The multi-center clinical phase IIb trial with Rabeximod in RA is expected to start recruitment of patients in the first half of 2020.

  • First Berlin Equity Research publishes updated independent analysis of Cyxone

    July 1, 2019 17:52 (CEST)

    Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.

  • Cyxone initiates first-in-human trial with T20K for the treatment of MS

    June 20, 2019 12:35 (CEST)
    Regulatory

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with drug candidate T20K for the treatment of multiple sclerosis (MS) immediately following the authorities’ approval. Currently, the focus is the recruitment and screening of healthy male volunteers for the study.

  • Cyxone submits application to start first-in-human trial with T20K in MS

    May 23, 2019 16:11 (CEST)
    Regulatory

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company has set a date for the application submission for the start of clinical trials with T20K. On Monday May 27, an application to the relevant authorities to start a first-in-human, phase I, clinical trial with drug candidate T20K in multiple sclerosis (MS) will be submitted. The company will subsequently await a response from the authorities before the study can be initiated as planned during the second quarter of 2019.

  • Cyxone forms a subsidiary in Switzerland

    May 20, 2019 13:23 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has initiated registration of Cyxone Switzerland AG, a wholly-owned subsidiary in Switzerland. The subsidiary, which is to be located in Basel, is an important step in strengthening the company’s global presence and opens up for a wider reach of international investments and collaborations.

  • Interim Report 1 January to 31 March 2019

    May 17, 2019 08:29 (CEST)
    Regulatory

    Summary of the interim report

  • Annual Report from Cyxone AB for the period 1 January 2018 to 31 December 2018

    April 2, 2019 08:02 (CEST)
    Regulatory

    Cyxone AB’s Annual Report for the financial year 2018 is now available at the company’s website (www.cyxone.com).

  • Cyxone announces strategic intent to position its drug candidate T20K in MS as a prophylactic agent

    March 20, 2019 10:01 (CET)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K as a prophylactic agent for the treatment of multiple sclerosis (MS). This indicates that the substance could be used to mitigate or prevent MS episodes and potentially even delay the disease progression. Early disease intervention, such as this, is currently not targeted by other treatments available.